Navigation Links
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Date:5/21/2008

of 48 weeks. Patients in any arm of this study with detectable virus at week 24 will be considered treatment failures and will discontinue treatment.

The primary efficacy endpoint of the study is sustained virologic response (SVR).(1) Secondary efficacy endpoints include early virologic response in patients who achieve SVR. The study will be stratified by HCV genotype 1 subtype 1a versus 1b, and baseline viral load.

Professor Jean-Pierre Bronowicki, M.D., Ph.D., department of hepato-gastroenterology, University Hospital of Nancy, France, and Jonathan McCone, M.D., director, Mount Vernon Endoscopy Center, Alexandria, Va., are the other co-principal investigators of this study.

Pivotal Study in Patients Who Failed Prior Treatment

The primary objective of this pivotal study, known as HCV RESPOND-2 (Retreatment with HCV Serine Protease Inhibitor Boceprevir and PEGINTRON/REBETOL) is to evaluate the efficacy of 36- and 48-week regimens of boceprevir (800 mg TID) in combination with PEGINTRON (1.5 mcg/kg/week) and REBETOL (600-1400 mg/day) compared to a control of PEGINTRON and REBETOL alone for 48 weeks in adult patients with chronic HCV genotype 1 who failed prior treatment with peginterferon and ribavirin combination therapy. The study is projected to enroll a total of 375 patients.

This study will enroll treatment-failure patients who have documented previous interferon responsiveness by achieving at least a 2 log decrease in viral load by week 12 of peginterferon and ribavirin therapy (nonresponders) or who were viral negative at end of peginterferon and ribavirin therapy, but did not obtain a sustained virologic response (relapsers). 'Null' responders -- those patients who do not meet the aforementioned criteria -- will not be enrolled in this study.

In this study, in the 36-week treatment arm, RVR criteria at 4 weeks of boceprevir treatment (treatment week 8) will be used to determine which boceprevir patients can stop all
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
4. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Schering-Plough Reports Top-Line Results of the IDEAL Study
7. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
8. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
9. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
10. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
11. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 CVS Health Corporation (NYSE: CVS ... May 1, 2015, at 8:30 a.m. (EDT) with analysts ... An audio webcast of the conference call ... of the CVS Health website for all interested parties. ... webcast will be archived and available on the web ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/dl9gbg/admetoxicology ) ... - Global Strategic Business Report" report to their ... for ADME-Toxicology Testing in US$ Million by the following ... The report provides separate comprehensive analytics for ... Japan , Europe , ...
(Date:4/17/2015)... 2015  Trovagene, Inc., (NASDAQ:  TROV) a developer ... data presented at the 2015 European Lung Cancer ... Monitoring ℠ (PCM) platform outperformed tissue biopsy ... T790M mutations in metastatic lung cancer patients. ... Mutation in Urinary Circulating Tumor DNA from Metastatic ...
Breaking Medicine Technology:ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
(Date:4/18/2015)... The Residential Senior Care Franchises ... years. The industry, which provides residential and personal-care services ... for themselves, has boomed on account of the aging ... seniors with memory impairment. As a result, IBISWorld expects ... 4.1% to $1.9 billion over the five years to ...
(Date:4/18/2015)... Carinsurancehints.com has released a new blog post explaining how to ... against fire damage. , Clients can now find auto ... is set intentionally on fire. This type of damages can ... things. , It is possible to compare the best ... , in just a few minutes. Clients should always ...
(Date:4/18/2015)... has released a new blog post explaining how to ... Clients can review important auto insurance quotes online, by ... advantages for clients who need affordable financial security for ... coverage for their vehicles can purchase a policy at ... agencies offer important discounts and drivers can learn more ...
(Date:4/18/2015)... New York, New York (PRWEB) April 18, 2015 ... http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) filed on behalf of individuals who ... hip replacement system continue to move forward in the ... an Order dated April 10th, the Court has amended ... joinder of unrelated cases. Among other things, the new ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Association Annual Conference to be held May 1-2, ... , The SCAPTA Annual Conference offers educational ... services. , Representatives from Aureus Medical’s ...
Breaking Medicine News(10 mins):Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2
... finds , THURSDAY, June 11 (HealthDay News) -- Mad cow ... somehow goes astray and deprives the healthy brain cells of ... considered a prion disease because it has been found to ... is found on the surface of many cells -- including ...
... ... media age. , ... (Vocus) June 11, 2009 -- From cyberbullying and violent video games to social networking and ... To help parents navigate this new and changing landscape, the Center on Media and ...
... of the crime in cancer are guilty of the initiation and ... disease, a team led by scientists at The University of Texas ... Cancer Cell . "We have a smoking gun" that ... that makes them are abnormally expressed in many types of cancer, ...
... Wii may help treat symptoms of Parkinson,s disease, including ... Parkinson,s disease is a degenerative disease that impairs ... game console, which simulates various sports and activities, could ... found additional benefits as well. "The Wii allows ...
... fifth most common malignancy worldwide and the third leading ... been associated with HCC. However, the relationship between type ... the effects of antidiabetic therapy on HCC risk have ... led by Dr. Valter Donadon from Pordenone Hospital addressed ...
... common cancers in China. Although the association between the ... the relation between smoking, alcohol drinking, family history of ... still remains uncertain. So it is important to investigate ... sporadic colorectal cancer. A research team led by ...
Cached Medicine News:Health News:Protein Branded As Culprit in Mad Cow Disease 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 3Health News:Researchers identify 4 new targets for breast cancer 2Health News:Wii-hab may enhance Parkinson's treatment 2
A full function instrument at an economical price....
... aspherical optics. The separation of illumination and ... optical system avoids corneal and iris reflex ... view the whole of the illuminated section ... pupil. Conventional ophthalmoscopes often let you see ...
... with superior aspherical optics. Includes XHL halogen ... beam by means of the aspherical optical ... The Beta 200 allows you to view ... the retina even with a small pupil. ...
Our standard ophthalmoscopes feature halogen light for true tissue color and consistent, long-lasting illumination, and six apertures for general and specialist use....
Medicine Products: